乙胆对人类牙血流的剂量相关影响
Tamás László Nagy1, Barbara Mikecs1, Zsolt M Lohinai1
1Department of Restorative Dentistry and Endodontics, Faculty of Dentistry, Semmelweis University, H-1088 Budapest, Szentkirályi utca 47, Budapest, Hungary.
BMC oral health
|November 17, 2024
概括
乙胆 (ACh) 在人类牙血流 (GBF) 中引起剂量依赖的血管扩张. 较高的ACH度会增加血液流动,只有最高剂量会导致远程血管扩张,这有助于微循环研究.
科学领域:
- 生理学 生理学 生理学
- 药理学 药理学是指药理学的学科.
- 微循环研究 微循环研究
背景情况:
- 研究了乙胆 (ACh) 对健康人牙血流 (GBF) 的剂量反应关系.
- 旨在了解与各种病理状况相关的血管扩张机制.
研究的目的:
- 为了确定乙胆对人类牙血流的剂量依赖作用.
- 探索乙胆在牙微循环中的作用.
主要方法:
- 采用激光光斑对比成像来测量年轻健康男性的非侵入性GBF.
- 用盐水作为对照剂,向牙硫注入不同剂量的甲基 (0.1,1,10 mg/mL).
- 使用线性混合模型对连续剂量应用和洗期的统计分析.
主要成果:
- 与盐水相比,所有ACH剂量的牙血流 (GBF) 在冠状区域显著增加.
- 在1和10 mg/mL ACh剂量时,在中途1区域观察到升高的GBF.
- 只有10毫克/毫升的ACh剂量有效地增加了GBF在中间2和顶部区域.
结论:
- 结果表明,在人类的牙微循环中,对乙胆的剂量依赖的血管扩张.
- 远程血管扩张 (3毫米) 只能通过最高的ACH度 (10毫克/毫升) 来诱导.
- 该方法促进了对内皮依赖的血管扩张在牙周炎和糖尿病等微循环障碍的研究.
相关概念视频
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
872
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
872
Cholinergic Receptors: Muscarinic
1.9K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
1.9K
Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.1K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.1K
Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.2K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.2K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
618
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
618
Drugs Acting on Autonomic Ganglia: Stimulants
1.3K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.3K


